Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year
survival is only 10%–20%. Chemotherapy is considered as the standard treatment for …

Cervical cancer (CC) caused by human papillomavirus (HPV) is one of the largest causes of
malignancies in women worldwide. Cisplatin is one of the widely used drugs for the …

Cisplatin is a valuable adjuvant to radiotherapy for the treatment of cervical cancer. Because
the advantage of combining cisplatin with radiotherapy is likely to be attributable to additive …

Cisplatin is the single most active cytotoxic agent in the treatment of patients with recurrent
or metastatic squamous cell cancer of the cervix; no other standard drug has been …

Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor
cells can acquire resistance to the damage caused by cisplatin, generating genetic and …

Cancer of the cervix is the second most common malignancy among women worldwide. The
last 20 years have lead to numerous advances in the medical management of locally …

OBJECTIVE.: Cisplatin-based combination therapy produces higher response rates and
improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer …

Metastatic disease is the most common mechanism of death in patients with advanced
bladder cancer. As for most solid tumors, chemotherapy remains the only realistic option for …

Introduction The prognosis of advanced/recurrent cervical cancer patients is generally poor
with 1-year survival ranging between 15 and 20%. Cisplatin (CDDP) based treatments are …

Purpose Cervical cancer represents the fourth most frequent malignancy in the world among
women, and mortality has remained stable for the past 4 decades. Intravenous cisplatin with …